Simulated Microgravity Influences VEGF, MAPK, and PAM Signaling in Prostate Cancer Cells.
Cell Line, Tumor
Cytoskeleton
/ genetics
Extracellular Matrix
/ genetics
Extracellular Matrix Proteins
/ genetics
Focal Adhesions
/ genetics
Gene Expression Regulation, Neoplastic
/ radiation effects
Humans
MAP Kinase Kinase 1
/ genetics
Male
Neoplasm Proteins
/ genetics
Phosphatidylinositol 3-Kinases
/ genetics
Prostatic Neoplasms
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
TOR Serine-Threonine Kinases
/ genetics
Vascular Endothelial Growth Factor A
/ genetics
Weightlessness Simulation
VEGF signaling
cytoskeleton
extracellular matrix
focal adhesion
microgravity
prostate cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Feb 2020
13 Feb 2020
Historique:
received:
23
11
2019
revised:
31
01
2020
accepted:
11
02
2020
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Prostate cancer is one of the leading causes of cancer mortality in men worldwide. An unusual but unique environment for studying tumor cell processes is provided by microgravity, either in space or simulated by ground-based devices like a random positioning machine (RPM). In this study, prostate adenocarcinoma-derived PC-3 cells were cultivated on an RPM for time periods of 3 and 5 days. We investigated the genes associated with the cytoskeleton, focal adhesions, extracellular matrix, growth, survival, angiogenesis, and metastasis. The gene expression of signaling factors of the vascular endothelial growth factor (VEGF), mitogen-activated protein kinase (MAPK), and PI3K/AKT/mTOR (PAM) pathways was investigated using qPCR. We performed immunofluorescence to study the cytoskeleton, histological staining to examine the morphology, and a time-resolved immunofluorometric assay to analyze the cell culture supernatants. When PC-3 cells were exposed to simulated microgravity (s-µ
Identifiants
pubmed: 32070055
pii: ijms21041263
doi: 10.3390/ijms21041263
pmc: PMC7072928
pii:
doi:
Substances chimiques
Extracellular Matrix Proteins
0
Neoplasm Proteins
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
MTOR protein, human
EC 2.7.1.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
MAP Kinase Kinase 1
EC 2.7.12.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsches Zentrum für Luft- und Raumfahrt
ID : 50WB1924
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Bone. 2011 Nov;49(5):965-74
pubmed: 21839189
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14058-63
pubmed: 18768801
Oncogene. 2000 Nov 20;19(49):5636-42
pubmed: 11114744
In Vitro Cell Dev Biol Anim. 2019 Apr;55(4):260-271
pubmed: 30820814
Biophys J. 1984 Sep;46(3):343-8
pubmed: 6487734
Cancer Genomics Proteomics. 2009 Sep-Oct;6(5):255-61
pubmed: 19996130
Planta. 1997;203 Suppl:S187-97
pubmed: 9299798
Cell Physiol Biochem. 2013;32(1):154-70
pubmed: 23867310
Int J Mol Sci. 2019 Jun 04;20(11):
pubmed: 31167392
Annu Rev Pathol. 2007;2:251-75
pubmed: 18039100
J Biol Chem. 2010 Nov 5;285(45):35068-78
pubmed: 20805229
Int J Mol Sci. 2017 Aug 10;18(8):
pubmed: 28796163
J Biol Chem. 1998 Nov 6;273(45):29979-85
pubmed: 9792718
Surgery. 1997 Aug;122(2):501-7
pubmed: 9288158
Sci Rep. 2015 Nov 18;5:16691
pubmed: 26576504
Cell Physiol Biochem. 2018;45(2):429-445
pubmed: 29402845
Int J Mol Sci. 2019 Mar 18;20(6):
pubmed: 30889841
Neoplasma. 2018;65(2):242-252
pubmed: 29534586
Anticancer Res. 2013 Apr;33(4):1343-50
pubmed: 23564771
PLoS One. 2015 Aug 14;10(8):e0135157
pubmed: 26274317
Angiogenesis. 2017 Nov;20(4):409-426
pubmed: 28660302
Expert Rev Proteomics. 2011 Feb;8(1):13-27
pubmed: 21329425
Physiol Rev. 2011 Jul;91(3):1071-121
pubmed: 21742796
In Vitro Cell Dev Biol Anim. 1997 May;33(5):375-80
pubmed: 9196896
J Biomed Mater Res A. 2013 Jul;101(7):2118-28
pubmed: 23427018
Stem Cells Dev. 2018 Jun 15;27(12):787-804
pubmed: 29596037
Sci Rep. 2018 Jan 17;8(1):921
pubmed: 29343717
Cell Biol Int. 1999;23(3):157-61
pubmed: 10562436
Eur J Cancer. 2014 Jan;50(2):457-68
pubmed: 24183378
Astrobiology. 2013 Jan;13(1):1-17
pubmed: 23252378
Curr Vasc Pharmacol. 2015;13(3):381-91
pubmed: 24548189
In Vitro Cell Dev Biol Anim. 1997 Jun;33(6):459-66
pubmed: 9201514
Neoplasia. 2013 Aug;15(8):925-38
pubmed: 23908593
Oncogene. 1999 Apr 1;18(13):2221-30
pubmed: 10327068
Biomed Res Int. 2015;2015:971474
pubmed: 25649075
Tissue Eng Part A. 2009 Aug;15(8):2267-75
pubmed: 19226201
Cell Physiol Biochem. 2011;28(2):185-98
pubmed: 21865726
Histopathology. 2012 Jan;60(1):59-74
pubmed: 22212078
J Biomol Screen. 2004 Jun;9(4):273-85
pubmed: 15191644
Cardiovasc Pathol. 2002 Jul-Aug;11(4):229-37
pubmed: 12140129
Mol Cancer Res. 2018 Mar;16(3):453-460
pubmed: 29330287
Cell Commun Signal. 2014 May 10;12:32
pubmed: 24885050
FASEB J. 2014 Feb;28(2):813-35
pubmed: 24196587
Int J Mol Sci. 2018 Aug 19;19(8):
pubmed: 30126252
BMC Cancer. 2009 May 06;9:134
pubmed: 19419554
Tissue Eng Part B Rev. 2014 Dec;20(6):555-66
pubmed: 24597549
Cell Physiol Biochem. 2016;40(1-2):1-17
pubmed: 27842307
Microgravity Sci Technol. 1994 Jul;7(2):207-10
pubmed: 11541854
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Biochim Biophys Acta. 1994 May 27;1198(1):11-26
pubmed: 8199193
Basic Clin Pharmacol Toxicol. 2016 Oct;119 Suppl 3:26-33
pubmed: 26826674
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Clin Cancer Res. 2011 Jul 1;17(13):4331-40
pubmed: 21622717
Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):322-8
pubmed: 18079407
J Biomed Inform. 2019 Dec;100:103320
pubmed: 31669288
Cell Tissue Res. 2006 May;324(2):267-77
pubmed: 16432709
FASEB J. 2012 Feb;26(2):639-55
pubmed: 22024737
BMC Nephrol. 2012 Feb 10;13:8
pubmed: 22325322
Am J Hum Genet. 1998 Dec;63(6):1588-93
pubmed: 9837810
Int J Mol Sci. 2018 Dec 12;19(12):
pubmed: 30545079
Nat Rev Cancer. 2006 Mar;6(3):184-92
pubmed: 16453012
J R Soc Interface. 2017 Feb;14(127):
pubmed: 28202590
Adv Space Res. 1992;12(1):145-52
pubmed: 11536950
Tumori. 1986 Oct 31;72(5):459-67
pubmed: 3798565
BMC Biochem. 2002 Dec 31;3:32
pubmed: 12509223
PLoS One. 2019 Jul 19;14(7):e0219363
pubmed: 31323026
Int J Mol Sci. 2018 Apr 23;19(4):
pubmed: 29690653
J Cell Biol. 2007 Dec 3;179(5):1043-57
pubmed: 18056416
Proteomics. 2018 Jul;18(13):e1800015
pubmed: 29785723
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006502
pubmed: 22762016
FASEB J. 2002 Apr;16(6):604-6
pubmed: 11919168
Nat Med. 2008 Dec;14(12):1351-6
pubmed: 19029981
FASEB J. 2019 Dec;33(12):14450-14460
pubmed: 31675484
J Cell Physiol. 2010 Jun;223(3):746-56
pubmed: 20205236
J Clin Invest. 2008 Sep;118(9):3051-64
pubmed: 18725989
Biochem J. 2001 Nov 15;360(Pt 1):255-64
pubmed: 11696015
J Cell Sci. 2012 Apr 15;125(Pt 8):1855-64
pubmed: 22544950
Sci Rep. 2016 May 27;6:26887
pubmed: 27230828
Biophys J. 2017 May 9;112(9):1885-1893
pubmed: 28494959
Mol Cell Biol. 1995 Feb;15(2):954-63
pubmed: 7529876
Dev Cell. 2012 Jan 17;22(1):146-57
pubmed: 22264731
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200510
J Urol. 1999 Jan;161(1):290-7
pubmed: 10037426
Endocrine. 2019 Aug;65(2):426-439
pubmed: 31129811
Cancer Sci. 2017 Jun;108(6):1157-1168
pubmed: 28375585
J Control Release. 2012 Dec 10;164(2):192-204
pubmed: 22613880
Genes Dev. 2000 Oct 1;14(19):2410-34
pubmed: 11018010
Trends Cell Biol. 2002 Mar;12(3):112-20
pubmed: 11859023
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Biol Chem. 1998 Nov 13;273(46):30336-43
pubmed: 9804796
Int J Mol Sci. 2019 Nov 15;20(22):
pubmed: 31731625
J Cell Mol Med. 2001 Jan-Mar;5(1):60-73
pubmed: 12067451
Oncogene. 1998 Dec 17;17(24):3157-67
pubmed: 9872331
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Mol Cancer Res. 2017 Nov;15(11):1469-1480
pubmed: 28811363
Adv Cancer Res. 2018;138:99-142
pubmed: 29551131
J Immunol. 2000 Feb 1;164(3):1169-74
pubmed: 10640727
Int J Mol Sci. 2019 May 24;20(10):
pubmed: 31137658
Cell Physiol Biochem. 2018;47(4):1729-1741
pubmed: 29949789